Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT516 in Hospitalized COVID-19 Patients With Hypoxia
NCT04363346Phase 1Completed
- Sponsor
- Masonic Cancer Center
- Start
- May 2020
- Primary completion
- Feb 2021
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of ft516 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Masonic Cancer Center. Primary endpoint: Dose Limiting Toxicity Events at 7 days. Started May 2020; status: completed.
02
Drugs
ft516
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04363346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04363346.